OBJECTIVE: The effect of a novel small molecule plasminogen activator inhibitor (PAI-1) inhibitor on adipose tissue physiology was investigated. METHODS AND RESULTS: In human preadipocyte cultures, PAI-039 inhibited both basal and glucose-stimulated increases in active PAI-1 antigen, yet had no effect on PAI-1 mRNA, suggesting a direct inactivation of PAI-1. Differentiation of human preadipocytes to adipocytes was associated with leptin synthesis, which was significantly reduced in the presence of PAI-039, together with an atypical adipocyte morphology characterized by a reduction in the size and number of lipid containing vesicles. In a model of diet-induced obesity, pair-fed C57 Bl/6 mice administered PAI-039 in a high-fat diet exhibited a dose-dependent reduction in body weight, epididymal adipose tissue weight, adipocyte volume, and circulating plasma active PAI-1. Plasma glucose, triglycerides, and leptin were also significantly reduced in drug-treated mice, and concentrations of PAI-039 associated with these physiological effects were near the in vitro IC50 for the inhibition of PAI-1. CONCLUSIONS: Our results indicate that a small molecule inactivator of PAI-1 can neutralize glucose-stimulated increases in PAI-1 in human preadipocyte cultures, reduce adipocyte differentiation, and prevent the development of diet-induced obesity. These data suggest the pharmacological inhibition of PAI-1 could be beneficial in diseases associated with expansion of adipose tissue mass.
OBJECTIVE: The effect of a novel small molecule plasminogen activator inhibitor (PAI-1) inhibitor on adipose tissue physiology was investigated. METHODS AND RESULTS: In human preadipocyte cultures, PAI-039 inhibited both basal and glucose-stimulated increases in active PAI-1 antigen, yet had no effect on PAI-1 mRNA, suggesting a direct inactivation of PAI-1. Differentiation of human preadipocytes to adipocytes was associated with leptin synthesis, which was significantly reduced in the presence of PAI-039, together with an atypical adipocyte morphology characterized by a reduction in the size and number of lipid containing vesicles. In a model of diet-induced obesity, pair-fed C57 Bl/6 mice administered PAI-039 in a high-fat diet exhibited a dose-dependent reduction in body weight, epididymal adipose tissue weight, adipocyte volume, and circulating plasma active PAI-1. Plasma glucose, triglycerides, and leptin were also significantly reduced in drug-treated mice, and concentrations of PAI-039 associated with these physiological effects were near the in vitro IC50 for the inhibition of PAI-1. CONCLUSIONS: Our results indicate that a small molecule inactivator of PAI-1 can neutralize glucose-stimulated increases in PAI-1 in human preadipocyte cultures, reduce adipocyte differentiation, and prevent the development of diet-induced obesity. These data suggest the pharmacological inhibition of PAI-1 could be beneficial in diseases associated with expansion of adipose tissue mass.
Authors: Jacqueline M Cale; Shih-Hon Li; Mark Warnock; Enming J Su; Paul R North; Karen L Sanders; Maria M Puscau; Cory D Emal; Daniel A Lawrence Journal: J Biol Chem Date: 2010-01-08 Impact factor: 5.157
Authors: J de Castro; J Sevillano; J Marciniak; R Rodriguez; C González-Martín; M Viana; O H Eun-suk; S Hauguel de Mouzon; E Herrera; M P Ramos Journal: Endocrinology Date: 2011-09-13 Impact factor: 4.736
Authors: Mark M Smits; Pier Woudstra; Kristina M Utzschneider; Jenny Tong; Fernando Gerchman; Mirjam Faulenbach; Darcy B Carr; Kathryn Aston-Mourney; Alan Chait; Robert H Knopp; James B Meigs; Edward J Boyko; Steven E Kahn Journal: Ann Epidemiol Date: 2013-03-25 Impact factor: 3.797
Authors: Nadine C El-Ayache; Shih-Hon Li; Mark Warnock; Daniel A Lawrence; Cory D Emal Journal: Bioorg Med Chem Lett Date: 2009-12-21 Impact factor: 2.823
Authors: Hekmat B Khoukaz; Yan Ji; Drew J Braet; Manisha Vadali; Ahmed A Abdelhamid; Cory D Emal; Daniel A Lawrence; William P Fay Journal: Arterioscler Thromb Vasc Biol Date: 2020-04-09 Impact factor: 8.311